Αποτελέσματα Αναζήτησης
15 Ιουλ 2024 · TREATMENT OF HSV-1 INFECTION. General principles — The management of HSV-1 infection in the immunocompetent host depends upon a variety of considerations, including: Whether the patient has primary HSV-1 infection or reactivation disease. The severity of symptoms.
- Valacyclovir (Valtrex) for Herpes Labialis. Med Lett Drugs Ther 2002; 44:95
Medline ® Abstract for Reference 8 of 'Treatment and...
- De Clercq E. Selective Anti-Herpesvirus Agents. Antivir Chem Chemother 2013; 23:93
1 PubMed | TI Selective anti-herpesvirus agents. AU De...
- Anna Wald, Md, MPH
Treatment and prevention of herpes simplex virus type 1 in...
- Spruance Sl, Nett R, Marbury T, Et Al. Acyclovir Cream for Treatment of Herpes Simplex Labialis: Results of Two Randomized, Double-Blind, Vehicle-Controlled, Multicenter Clinical Trials. Antimicrob Agents Chemother 2002; 46:2238
Healthy adults with a history of frequent herpes labialis...
- Nikkels Af, Pièrard Ge. Treatment of Mucocutaneous Presentations of Herpes Simplex Virus Infections. Am J Clin Dermatol 2002; 3:475
Nikkels Af, Pièrard Ge. Treatment of Mucocutaneous...
- Jensen La, Hoehns Jd, Squires Cl. Oral Antivirals for The Acute Treatment of Recurrent Herpes Labialis. Ann Pharmacother 2004; 38:705
DATA SOURCES A literature search was performed in MEDLINE...
- Rahimi H, Mara T, Costella J, Et Al. Effectiveness of Antiviral Agents for The Prevention of Recurrent Herpes Labialis: a Systematic Review and Meta-Analysis. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 113:618
Medline ® Abstract for Reference 42 of 'Treatment and...
- Valacyclovir (Valtrex) for Herpes Labialis. Med Lett Drugs Ther 2002; 44:95
This review focuses on conventional methods for evaluating the efficacy of a herpes vaccine using differential CD8 + T cells and important unaccounted immune aspects for designing an effective vaccine against herpes.
5 Μαΐ 2024 · Unlike prophylactic vaccines, in which the correlate of immunity is antibody function, T cell immunity is the correlate of immunity for the only effective therapeutic herpesvirus vaccine–zoster vaccine.
24 Απρ 2022 · The latest failures of most of the clinical herpes vaccines indicate that immunotherapeutic vaccine against HSV should be efficient in eliciting antigen-specific immune responses that contain reactivation of the virus, to control both recurrent lesions and viral shedding.
6 Δεκ 2021 · Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in Guinea pigs compared to immunization with gD alone.
25 Ιουλ 2024 · Ideally, a single dose for primary immunization, but two or three doses could be acceptable for strong and long-lasting immunity. Depending on the vaccine platform and formulation, two to three doses might be needed for primary immunization.
Immunity should be durable, preferably lasting multiple years between booster doses. A successful genital herpes vaccine should also protect against HSV-1 genital infection because approximately 50% of first-time genital herpes infections in resource-rich countries are caused by HSV-1 [10, 16, 17].
